Development of PARP and Immune-Checkpoint Inhibitor Combinations
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
PARP inhibitors drive increased DNA damage, particularly in tumors with existing defects in DNA repair. This damage not only promotes immune priming through a range of molecular mechanisms, but also leads to adaptive upregulation of programmed death ligand 1 (PD-L1) expression. In this context, PARP inhibition and programmed cell death 1(PD-1)/PD-L1-targeting antibodies represent a rationale combination. In this review, we detail the basic and translational science underpinning this promising new combination, summarize available clinical data, and discuss the key questions that remain to be addressed during future development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tumors with DNA damage repair (DDR) defects, exemplified by MSI-H/dMMR status, were predicted to have high rates of neoantigen formation due to their high mutational load (approximately 10-fold compared with that of MMR-proficient tumors) and therefore higher rates of response to ICT (136).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [136]
In the citing paper
“Besides synthetic lethal effect, PARP inhibitor (PARPi) modulates the TME and promotes the antitumor immune response [223].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [223]
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“Around the same time, early clinical trial data generated significant enthusiasm for targeting an alternative receptor, PD-1 (23).”
BackgroundComprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 1×
“However, in cells with mutations in breast cancer 1 (BRCA1) or BRCA2, HR is defective, and loss of PARP function results in the accumulation of DSBs and eventual cell death (4, 5).”
BackgroundMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 2×
“This hypothesis has proved to be correct, as a number of antibodies targeting PD-1/PD-L1 have shown broad clinical activity, leading to regulatory approval for the treatment of multiple cancers (25), including melanoma (26, 27), squamous cell cancer of the head and neck (28, 29), Hodgkin lymphoma (30, 31), urothelial…”
BackgroundResultNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 1×
“This hypothesis has proved to be correct, as a number of antibodies targeting PD-1/PD-L1 have shown broad clinical activity, leading to regulatory approval for the treatment of multiple cancers (25), including melanoma (26, 27), squamous cell cancer of the head and neck (28, 29), Hodgkin lymphoma (30, 31), urothelial…”
BackgroundSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Research works printed but not linked: 1
- Ledermann, 2015, Correction to Lancet Oncol 2014; 15: 856. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, Lancet Oncol, 16, e158
Cited by
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
“Besides synthetic lethal effect, PARP inhibitor (PARPi) modulates the TME and promotes the antitumor immune response [223].”
BackgroundThe Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Poly(ADP-ribose) polymerase inhibition: past, present and future
Curtin, N. J., & Szabo, C. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0076-6 · Cited by 556
Westin, S. N., Moore, K., Chon, H. S., Lee, J.-Y., Thomes Pepin, J., Sundborg, M., Shai, A., de la Garza, J., Nishio, S., Gold, M. A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02132 · Cited by 380
Development of Immunotherapy Combination Strategies in Cancer
Yap, T. A., Parkes, E. E., Peng, W., Moyers, J. T., Curran, M. A., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1209 · Cited by 330
Metadata
- Authors
- Stewart, R. A., Pilié, P. G., & Yap, T. A.
- Affiliations
- Pfizer (United States) (US)
- 2Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Stewart, Ross A
- Venue
- Cancer Research
- Published
- 2018-12-13
- Volume
- 78
- Issue
- 24
- Pages
- 6717-6725
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2902324525
- Cited by
- 239
- References
- 110
- Citations by year
- 2026: 11 · 2025: 23 · 2024: 25 · 2023: 36 · 2022: 44 · 2021: 44 · 2020: 38 · 2019: 17
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- PARP inhibitors, immune checkpoint inhibitors, PD-1/PD-L1 blockade, combination therapy, DNA repair deficiency, PD-L1 upregulation, DNA damage, cancer immunotherapy
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, Antibodies, Antineoplastic Combined Chemotherapy Protocols, DNA Damage, Humans, Immune System, Immunotherapy, Inflammation, Neoplasms, Cell Death, Disease Progression, Translational Research, Biomedical, B7-H1 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of PARP and Immune-Checkpoint Inhibitor Combinations. https://app.cochat.ai/papers/10.1158/0008-5472.can-18-2652
- The paper
- Stewart, R. A., Pilié, P. G., & Yap, T. A. (2018). Development of PARP and Immune-Checkpoint Inhibitor Combinations. Cancer Research. https://doi.org/10.1158/0008-5472.can-18-2652
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.